Published in Schizophr Bull on January 25, 2007
Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry (2008) 9.54
At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry (2011) 3.66
Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull (2007) 3.15
Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull (2009) 2.90
The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr Res (2010) 2.78
Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) (2008) 2.64
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry (2010) 2.54
Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry (2014) 2.47
North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. Schizophr Res (2012) 1.79
Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Interv Psychiatry (2010) 1.71
A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol Psychiatry (2010) 1.62
Are screening instruments valid for psychotic-like experiences? A validation study of screening questions for psychotic-like experiences using in-depth clinical interview. Schizophr Bull (2009) 1.49
Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study. Hum Brain Mapp (2015) 1.46
Risk factors for psychosis: impaired social and role functioning. Schizophr Bull (2011) 1.43
Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res (2012) 1.32
Emotion processing in persons at risk for schizophrenia. Schizophr Bull (2008) 1.31
Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. Schizophr Res (2007) 1.29
Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One (2012) 1.28
Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull (2009) 1.27
Attenuated psychosis syndrome in DSM-5. Schizophr Res (2013) 1.24
The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res (2009) 1.21
The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr Bull (2007) 1.19
Identification and characterization of prodromal risk syndromes in young adolescents in the community: a population-based clinical interview study. Schizophr Bull (2011) 1.17
The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res (2010) 1.14
Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull (2010) 1.13
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry (2008) 1.13
McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry (2010) 1.11
Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study. Schizophr Res (2013) 1.06
Stress and neurodevelopmental processes in the emergence of psychosis. Neuroscience (2013) 1.05
North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms. J Nerv Ment Dis (2015) 1.02
Progressive structural brain changes during development of psychosis. Schizophr Bull (2010) 1.01
Multivariate prediction of emerging psychosis in adolescents at high risk for schizophrenia. Schizophr Res (2012) 1.01
Reliability of neuroanatomical measurements in a multisite longitudinal study of youth at risk for psychosis. Hum Brain Mapp (2013) 0.99
Premorbid functional development and conversion to psychosis in clinical high-risk youths. Dev Psychopathol (2013) 0.99
Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol (2012) 0.97
A stratified model for psychosis prediction in clinical practice. Schizophr Bull (2014) 0.97
Kraepelin and psychotic prodromal conditions. Eur Arch Psychiatry Clin Neurosci (2008) 0.96
Structural Brain Abnormalities in Youth With Psychosis Spectrum Symptoms. JAMA Psychiatry (2016) 0.94
How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up. Schizophr Bull (2008) 0.94
Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011. Schizophr Res (2013) 0.90
Recruitment strategies for the detection of individuals at clinical high risk of developing psychosis. Epidemiol Psychiatr Sci (2012) 0.90
Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome. Neuropharmacology (2012) 0.89
The development of psychotic disorders in adolescence: a potential role for hormones. Horm Behav (2013) 0.88
"Attenuated psychotic symptoms syndrome" as a risk syndrome of psychosis, diagnosis in DSM-V: The debate. Indian J Psychiatry (2011) 0.88
Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis. Schizophr Bull (2015) 0.87
Deficient Suppression of Default Mode Regions during Working Memory in Individuals with Early Psychosis and at Clinical High-Risk for Psychosis. Front Psychiatry (2013) 0.87
Should "risk syndrome for psychosis" be included as a diagnosis in DSM-V? World Psychiatry (2010) 0.86
Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiatry Res (2011) 0.86
Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation. J Psychiatr Res (2011) 0.85
How can studies of resting-state functional connectivity help us understand psychosis as a disorder of brain development? Curr Opin Neurobiol (2014) 0.85
Correspondence between psychometric and clinical high risk for psychosis in an undergraduate population. Psychol Assess (2014) 0.84
EARLY DETECTION AND INTERVENTION FOR PSYCHOSIS: PERSPECTIVES FROM NORTH AMERICA. Clin Neuropsychiatry (2008) 0.84
Recent advances in understanding schizophrenia. F1000Prime Rep (2014) 0.83
Treatment implications of the schizophrenia prodrome. Curr Top Behav Neurosci (2010) 0.82
Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium. Early Interv Psychiatry (2014) 0.82
Functional development in clinical high risk youth: prediction of schizophrenia versus other psychotic disorders. Psychiatry Res (2013) 0.81
Impact of Trauma on Attenuated Psychotic Symptoms. Psychosis (2012) 0.81
Connectome-wide network analysis of youth with Psychosis-Spectrum symptoms. Mol Psychiatry (2015) 0.81
Prevention of the first episode of psychosis. Psychiatr Clin North Am (2010) 0.80
The development of the Content of Attenuated Positive Symptoms Codebook for those at clinical high risk of psychosis. Psychosis (2011) 0.80
Strategies for effective recruitment of individuals at risk for developing psychosis. Early Interv Psychiatry (2011) 0.80
Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task. J Psychiatry Neurosci (2013) 0.79
A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I. Ann Clin Transl Neurol (2016) 0.79
Youth-caregiver agreement on clinical high-risk symptoms of psychosis. J Abnorm Child Psychol (2014) 0.79
Developmental mechanisms in the prodrome to psychosis. Dev Psychopathol (2013) 0.79
The 'at-risk mental state' for psychosis in adolescents: clinical presentation, transition and remission. Child Psychiatry Hum Dev (2014) 0.78
Severity of thought disorder predicts psychosis in persons at clinical high-risk. Schizophr Res (2015) 0.78
Current status specifiers for patients at clinical high risk for psychosis. Schizophr Res (2014) 0.77
Multisite reliability of MR-based functional connectivity. Neuroimage (2016) 0.77
Using human brain imaging studies as a guide toward animal models of schizophrenia. Neuroscience (2015) 0.76
The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions. Schizophr Res (2012) 0.76
Early Recognition of High Risk of Bipolar Disorder and Psychosis: An Overview of the ZInEP "Early Recognition" Study. Front Public Health (2014) 0.76
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response. Physiol Behav (2012) 0.76
Common Measures for National Institute of Mental Health Funded Research. Biol Psychiatry (2016) 0.75
Working with Asian American youth at clinical high risk for psychosis: a case illustration. J Nerv Ment Dis (2013) 0.75
Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis. Schizophr Bull (2016) 0.75
Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample. Acta Psychiatr Scand (2015) 0.75
Ethical considerations when treating patients with schizophrenia. Psychiatry (Edgmont) (2008) 0.75
Potentially important periods of change in the development of social and role functioning in youth at clinical high risk for psychosis. Dev Psychopathol (2017) 0.75
The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry (1992) 7.36
Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull (2003) 7.11
Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior. Am J Ment Defic (1981) 6.62
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry (2002) 4.60
Psychometric properties of the life events checklist. Assessment (2004) 3.93
Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull (1982) 3.63
Exemplification of a method for scaling life events: the Peri Life Events Scale. J Health Soc Behav (1978) 3.48
Strauss (1969) revisited: a psychosis continuum in the general population? Schizophr Res (2000) 2.74
Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr Bull (2003) 2.04
Assessing traumatic event exposure: general issues and preliminary findings for the Stressful Life Events Screening Questionnaire. J Trauma Stress (1998) 2.01
A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull (1988) 1.65
Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull (2001) 1.53
The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry (2005) 1.52
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res (2003) 1.47
Prevention of missing data in clinical research studies. Biol Psychiatry (2006) 1.32
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res (2003) 1.29
Early detection and intervention of schizophrenia: rationale and research. Br J Psychiatry Suppl (1998) 1.26
Overcoming barriers to research in early serious mental illness: issues for future collaboration. Schizophr Bull (2003) 1.17
First-episode psychosis in the military: a comparative study of prodromal symptoms. Aust N Z J Psychiatry (2001) 1.13
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Automatically parcellating the human cerebral cortex. Cereb Cortex (2004) 18.32
Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry (2010) 16.89
Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet (2009) 12.96
Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry (2008) 9.54
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull (2003) 7.11
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A (2009) 6.09
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry (2002) 4.60
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry (2006) 4.18
The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 4.16
Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia. Neuroimage (2004) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Distinct genetic influences on cortical surface area and cortical thickness. Cereb Cortex (2009) 3.90
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry (2011) 3.66
The Collaborative Longitudinal Personality Disorders Study (CLPS): overview and implications. J Pers Disord (2005) 3.51
Plausibility and possible determinants of sudden "remissions" in borderline patients. Psychiatry (2003) 3.29
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology (2009) 3.27
Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry (2008) 3.27
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry (2006) 3.17
Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull (2007) 3.15
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry (2005) 3.08
Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. Am J Psychiatry (2002) 2.99
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull (2009) 2.90
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr Res (2010) 2.78
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol (2005) 2.62
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry (2010) 2.54
The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull (2006) 2.53
Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull (2005) 2.50
Cortical thinning of the attention and executive function networks in adults with attention-deficit/hyperactivity disorder. Cereb Cortex (2006) 2.44
Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Arch Gen Psychiatry (2011) 2.33
Amygdala hyperreactivity in borderline personality disorder: implications for emotional dysregulation. Biol Psychiatry (2003) 2.31
Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol (2004) 2.30
Hierarchical genetic organization of human cortical surface area. Science (2012) 2.28
Hormonal cycle modulates arousal circuitry in women using functional magnetic resonance imaging. J Neurosci (2005) 2.25
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 2.22
Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am J Psychiatry (2005) 2.18
Axis I and axis II disorders as predictors of prospective suicide attempts: findings from the collaborative longitudinal personality disorders study. J Abnorm Psychol (2003) 2.17
Identification and treatment of a pineal region tumor in an adolescent with prodromal psychotic symptoms. Am J Psychiatry (2010) 2.12
Contributions of genetic risk and fetal hypoxia to hippocampal volume in patients with schizophrenia or schizoaffective disorder, their unaffected siblings, and healthy unrelated volunteers. Am J Psychiatry (2002) 2.08
Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci U S A (2007) 2.04
Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr Bull (2003) 2.04
Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry (2005) 2.03
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr Res (2009) 1.98
Implications for the neural basis of social cognition for the study of schizophrenia. Am J Psychiatry (2003) 1.98
Stability of functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder over two years. Psychol Med (2005) 1.97
Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. J Consult Clin Psychol (2004) 1.96
Genetic and environmental influences on the size of specific brain regions in midlife: the VETSA MRI study. Neuroimage (2009) 1.94
Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2011) 1.93
Diffusion tensor imaging of the superior longitudinal fasciculus and working memory in recent-onset schizophrenia. Biol Psychiatry (2007) 1.89
Borderline personality disorder criteria associated with prospectively observed suicidal behavior. Am J Psychiatry (2004) 1.89
The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull (2006) 1.88
Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol Psychiatry (2013) 1.87